Proliferation of human hepatocellular carcinoma cells from surgically resected specimens under conditionally reprogrammed culture

Wang,Zhenglu; Bi,Bowen; Song,Hongli; Liu,Lei; Zheng,Hong; Wang,Shusen; Shen,Zhongyang

doi:10.3892/mmr.2019.10160

Proliferation of human hepatocellular carcinoma cells from surgically resected specimens under conditionally reprogrammed culture

Authors:
- Zhenglu Wang
- Bowen Bi
- Hongli Song
- Lei Liu
- Hong Zheng
- Shusen Wang
- Zhongyang Shen
View Affiliations

Affiliations: Pathology Department, Tianjin First Center Hospital, Tianjin 300192, P.R. China, Biological Sample Resource Sharing Center, Tianjin First Center Hospital, Tianjin 300192, P.R. China, Organ Transplantation Department, Tianjin First Center Hospital, Tianjin 300192, P.R. China, Key Laboratory for Critical Care Medicine of the Ministry of Health, Tianjin 300192, P.R. China, Key Laboratory of Transplant Medicine, Chinese Academy of Medical Sciences, Tianjin 300192, P.R. China, Tianjin Key Laboratory for Organ Transplantation, Tianjin 300192, P.R. China
Published online on: April 12, 2019 https://doi.org/10.3892/mmr.2019.10160
Pages: 4623-4630
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is the third most common cause of cancer mortality worldwide, which is partially due to the lack of appropriate therapeutic options. The development of HCC is accompanied with unique and continuous genomic and epigenetic modifications. Therefore, the absence of a personalized and reproducible human model reduces the ability to determine the potential of candidate treatments. Conditional reprogramming (CR) culture has been used to establish and indefinitely grow patient‑derived tumor cell lines in a rapid and efficient manner. In the present study, primary HCC cells were isolated from tumor specimens and cultured under CR conditions. The proliferative potential and capacity of cells to undergo continuous regeneration were evaluated by cell viability and proliferation assays, and the expression of tumor‑specific markers was determined by western blotting and immunofluorescence to determine the prospects for use in clinical settings. It was demonstrated that ~55% of tumor samples were able to generate HCC cells that could be continuously expanded and passaged under CR conditions; this ability was associated with the source and composition of the tumor tissues. Furthermore, the expression of the tumor‑specific marker α‑fetoprotein and the proliferative ability of cells were maintained following cycles of cryopreservation and resuscitation. In conclusion, with further optimization, the CR system may be a useful tool for the precise therapeutic treatment of patients with HCC.

View Figures

View References

1	Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M and Negri E: Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 67:302–309. 2017. View Article : Google Scholar : PubMed/NCBI
2	Ghouri YA, Mian I and Rowe JH: Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog. 16:12017. View Article : Google Scholar : PubMed/NCBI
3	Chan SL and Yeo W: Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights. World J Gastroenterol. 20:3135–3145. 2014. View Article : Google Scholar : PubMed/NCBI
4	Tovoli F, Granito A, De Lorenzo S and Bolondi L: Regorafenib for the treatment of hepatocellular carcinoma. Drugs Today (Barc). 54:5–13. 2018. View Article : Google Scholar : PubMed/NCBI
5	Thorgeirsson SS and Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
6	Lohitesh K, Chowdhury R and Mukherjee S: Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: An insight. Cancer Cell Int. 18:442018. View Article : Google Scholar : PubMed/NCBI
7	Huch M, Gehart H, van Boxtel R, Hamer K, Blokzijl F, Verstegen MM, Ellis E, van Wenum M, Fuchs SA, de Ligt J, et al: Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell. 160:299–312. 2015. View Article : Google Scholar : PubMed/NCBI
8	Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, Timofeeva OA, Nealon C, Dakic A, Simic V, et al: ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol. 180:599–607. 2012. View Article : Google Scholar : PubMed/NCBI
9	Liu X, Krawczyk E, Suprynowicz FA, Palechor-Ceron N, Yuan H, Dakic A, Simic V, Zheng YL, Sripadhan P, Chen C, et al: Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens. Nat Protoc. 12:439–451. 2017. View Article : Google Scholar : PubMed/NCBI
10	Mahajan AS, Sugita BM, Duttargi AN, Saenz F, Krawczyk E, McCutcheon JN, Fonseca AS, Kallakury B, Pohlmann P, Gusev Y, et al: Genomic comparison of early-passage conditionally reprogrammed breast cancer cells to their corresponding primary tumors. PLoS One. 12:e01861902017. View Article : Google Scholar : PubMed/NCBI
11	Alamri AM, Kang K, Groeneveld S, Wang W, Zhong X, Kallakury B, Hennighausen L, Liu X and Furth PA: Primary cancer cell culture: Mammary-optimized vs conditional reprogramming. Endocr Relat Cancer. 23:535–554. 2016. View Article : Google Scholar : PubMed/NCBI
12	Gao B, Huang C, Kernstine K, Pelekanou V, Kluger Y, Jiang T, Peters-Hall JR, Coquelin M, Girard L, Zhang W, et al: Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget. 8:11114–11126. 2017.PubMed/NCBI
13	Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi JP, Yadav B, Paavolainen L, Aittokallio T, Heckman C, Wennerberg K, et al: Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. Eur Urol. 71:319–327. 2017. View Article : Google Scholar : PubMed/NCBI
14	Timofeeva OA, Palechor-Ceron N, Li G, Yuan H, Krawczyk E, Zhong X, Liu G, Upadhyay G, Dakic A, Yu S, et al: Conditionally reprogrammed normal and primary tumor prostate epithelial cells: A novel patient-derived cell model for studies of human prostate cancer. Oncotarget. 8:22741–22758. 2017. View Article : Google Scholar : PubMed/NCBI
15	Sette G, Salvati V, Giordani I, Pilozzi E, Quacquarini D, Duranti E, De Nicola F, Pallocca M, Fanciulli M, Falchi M, et al: Conditionally reprogrammed cells (CRC) methodology does not allow the in vitro expansion of patient-derived primary and metastatic lung cancer cells. Int J Cancer. 143:88–99. 2018. View Article : Google Scholar : PubMed/NCBI
16	Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarró LM, Bradshaw CR, Allen GE, Arnes-Benito R, Sidorova O, Gaspersz MP, et al: Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 23:1424–1435. 2017. View Article : Google Scholar : PubMed/NCBI
17	World Medical A; World Medical Association, : World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 310:2191–2194. 2013. View Article : Google Scholar : PubMed/NCBI
18	Thery C, Amigorena S, Raposo G and Clayton A: Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 30:3.22.1–3.22.29. 2006. View Article : Google Scholar
19	Zhu Y, Yang Y, Guo J, Dai Y, Ye L, Qiu J, Zeng Z, Wu X, Xing Y, Long X, et al: Ex vivo 2D and 3D HSV-2 infection model using human normal vaginal epithelial cells. Oncotarget. 8:15267–15282. 2017.PubMed/NCBI
20	Plaks V, Kong N and Werb Z: The cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 16:225–238. 2015. View Article : Google Scholar : PubMed/NCBI
21	Agarwal S and Rimm DL: Making every cell like HeLa a giant step for cell culture. Am J Pathol. 180:443–445. 2012. View Article : Google Scholar : PubMed/NCBI
22	Suprynowicz FA, Upadhyay G, Krawczyk E, Kramer SC, Hebert JD, Liu X, Yuan H, Cheluvaraju C, Clapp PW, Boucher RC Jr, et al: Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells. Proc Natl Acad Sci USA. 109:20035–20040. 2012. View Article : Google Scholar : PubMed/NCBI
23	Gillet JP, Varma S and Gottesman MM: The clinical relevance of cancer cell lines. J Natl Cancer Inst. 105:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
24	Hensley CT, Wasti AT and DeBerardinis RJ: Glutamine and cancer: Cell biology, physiology, and clinical opportunities. J Clin Invest. 123:3678–3684. 2013. View Article : Google Scholar : PubMed/NCBI
25	Yu F, Lu Y, Tao L, Jiang YY, Lin DC, Wang L, Petersson F, Yoshiyama H, Koeffler PH, Goh BC, et al: Non-malignant epithelial cells preferentially proliferate from nasopharyngeal carcinoma biopsy cultured under conditionally reprogrammed conditions. Sci Rep. 7:173592017. View Article : Google Scholar : PubMed/NCBI
26	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
27	McMahon BJ, Alberts SR, Wainwright RB, Bulkow L and Lanier AP: Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med. 150:1051–1054. 1990. View Article : Google Scholar : PubMed/NCBI
28	Zhang BH, Yang BH and Tang ZY: Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 130:417–422. 2004. View Article : Google Scholar : PubMed/NCBI